, dpa-AFX

DGAP-News: Endgültige Zuteilung der Wandelanleihe der Zur Rose im Betrag von etwa CHF 95 Mio. (deutsch)

Endgültige Zuteilung der Wandelanleihe der Zur Rose im  Betrag von etwa CHF 95 Mio.

Zur Rose Group AG / Schlagwort(e): Kapitalmaßnahme
Endgültige Zuteilung der Wandelanleihe der Zur Rose im Betrag von etwa CHF
95 Mio.

13.09.2022 / 09:25 CET/CEST

---------------------------------------------------------------------------

   Not for release, publication or distribution in whole or in part in or
   into the United States, Canada,
   Australia or Japan or any other jurisdiction in which the distribution
   or release would be unlawful.
   Frauenfeld, 13. September 2022
   Medienmitteilung
Endgültige Zuteilung der Wandelanleihe der Zur Rose im Betrag von etwa CHF
95 Mio.

Nach der erfolgreichen Platzierung und vorläufigen Zuteilung einer
unbesicherten Wandelanleihe der Zur Rose Group AG (die "Gesellschaft" oder
"Zur Rose Group") am 1. September 2022 im Betrag von etwa CHF 95 Mio. mit
einer Fälligkeit im Jahr 2026 und nach Ablauf des Zeitraums zur Ausübung der
Vorwegzeichnungsrechte am 12. September 2022 erfolgte heute die endgültige
Zuteilung der Wandelanleihe. Details der endgültigen Zuteilung werden den
teilnehmenden institutionellen Investoren heute mitgeteilt.

Bis zum 12. September 2022, 12:00 Uhr mittags MESZ wurden 1'993'560
Vorwegzeichnungsrechte durch dazu berechtigte Aktionäre ausgeübt. Dies
entspricht 16'613 Wandelanleihen (etwa 17.5% des gesamten Ausgabevolumens im
Betrag von etwa CHF 95 Mio.). Infolgedessen wurden die bisher vorläufig
erfolgten Zuteilungen an die institutionellen Investoren, die am
Bookbuilding-Verfahren am 1. September 2022 teilgenommen haben, pro rata
gekürzt ("Clawback"). Im Ergebnis erhielten diese institutionellen
Investoren eine endgültige Zuteilung von Wandelanleihen im Gesamtbetrag von
etwa CHF 78.4 Mio., während anspruchsberechtigten Aktionären nach Ausübung
ihrer Vorwegzeichnungsrechte Wandelanleihen im Gesamtbetrag von etwa CHF
16.6 Mio. endgültig zugeteilt wurden.

BofA Securities, Goldman Sachs Bank Europe SE und die UBS AG agierten als
gemeinsame Bookrunner für die Wandelanleihe.

Baker McKenzie agierte als rechtliche Beraterin der Zur Rose Group.

Kontakt für Analysten und Investoren
Dr. Daniel Grigat, Head of Investor Relations
Email: ir@zurrose.com, Telefon: +41 58 810 11 49

Kontakt für Medien
Lisa Lüthi, Group Director Communications
Email: media@zurrose.com, Telefon: +41 52 724 08 14

Agenda

20. Oktober 2022 Q3/2022 Trading Update
19. Januar 2023 Umsatz 2022
23. März 2023 Jahresergebnis 2022
20. April 2023 Q1/2023 Trading Update
4. Mai 2023 Ordentliche Generalversammlung

Zur Rose-Gruppe

Die Schweizer Zur Rose-Gruppe ist Europas grösste E-Commerce-Apotheke und
eine der führenden Ärztegrossistinnen in der Schweiz. Darüber hinaus
betreibt sie den in Südeuropa führenden Marktplatz für apothekenübliche
Gesundheits- und Pflegeprodukte. Das Unternehmen ist international mit
starken Marken präsent, unter anderem mit Deutschlands bekanntester
Apothekenmarke DocMorris. Zur Rose beschäftigt an ihren Standorten in der
Schweiz, Deutschland, den Niederlanden, Spanien und Frankreich über 2'400
Mitarbeiter. Im Jahr 2021 erwirtschaftete sie einen Aussenumsatz von 2'034
Millionen Franken bei derzeit über 11 Millionen aktiven Kunden in
Kernmärkten Europas.

Mit ihrem Geschäftsmodell bietet die Zur Rose-Gruppe eine qualitativ
hochwertige, sichere und kostengünstige pharmazeutische Versorgung sowie
digitale Services im Bereich Marktplatz, Ökosystem, Technologie und
Telemedizin. Darüber hinaus treibt Zur Rose die Positionierung als
umfassende Gesundheitsdienstleisterin aktiv voran. Im Zentrum steht der Auf-
und Ausbau des europäischen Gesundheitsökosystems, auf welchem sich
qualifizierte Anbieter mit Produkten, Dienstleistungen und digitalen
Lösungen vernetzen. Der Anspruch von Zur Rose ist es, kundenzentrierte
Behandlungspfade anzubieten, damit Menschen eine optimale Versorgung sowie
Medikations- und Therapieoptionen erhalten. Zur Rose verfolgt damit die
Vision, eine Welt zu schaffen, in der die Menschen die eigene Gesundheit mit
nur einem Klick managen können.

Die Aktien der Zur Rose Group AG sind an der SIX Swiss Exchange kotiert
(Valor 4261528, ISIN CH0042615283, Ticker ROSE). Weitere Informationen unter
zurrosegroup.com.

Disclaimer

THE CONTENTS OF THIS ANNOUNCEMENT HAVE BEEN PREPARED BY AND ARE THE SOLE
RESPONSIBILITY OF ZUR ROSE GROUP AG (THE "COMPANY") AND ZUR ROSE FINANCE
B.V. (THE "ISSUER"). THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR
BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR COMPLETE. NO
RELIANCE MAY BE PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION
CONTAINED IN THIS ANNOUNCEMENT OR ITS ACCURACY, FAIRNESS OR COMPLETENESS.

THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR
OR PURCHASE ANY SECURITIES TO ANY PERSON IN THE UNITED STATES, AUSTRALIA,
CANADA, ITALY, JAPAN, SOUTH AFRICA OR IN ANY JURISDICTION TO WHOM OR IN
WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL. IT IS NOT BEING ISSUED IN
COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN
MAY BE RESTRICTED OR PROHIBITED BY LAW,

THIS INFORMATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA AND SHOULD NOT BE
DISTRIBUTED TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES.
THE DISTRIBUTION OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN
JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT OR OTHER
INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND
OBSERVE SUCH RESTRICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY
CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
SECURITIES OF THE COMPANY OR THE ISSUER ARE NOT BEING PUBLICLY OFFERED
OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF THE COMPANY AND THE
ISSUER REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES
UNLESS REGISTERED UNDER THE US SECURITIES ACT OF 1933 (THE "SECURITIES ACT")
OR OFFERED IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT. THE SECURITIES REFERRED TO HEREIN HAVE
NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR UNDER THE
APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA OR JAPAN. SUBJECT TO CERTAIN
EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED, SOLD OR
DELIVERED WITHIN THE UNITED STATES OR TO OR FOR THE ACCOUNT OF U.S. PERSONS
EXCEPT IN AN "OFFSHORE TRANSACTION" IN ACCORDANCE WITH REGULATION S UNDER
THE SECURITIES ACT OR FOR THE ACCOUNT OR BENEFIT OF ANY NATIONAL, RESIDENT
OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN. THIS DOCUMENT DOES NOT CONSTITUTE
A PROSPECTUS ACCORDING TO THE SWISS FEDERAL ACT ON FINANCIAL SERVICES.

IN EACH MEMBER STATE OF THE EUROPEAN ECONOMIC AREA AND THE UNITED KINGDOM
(EACH, A "RELEVANT STATE"), THIS ANNOUNCEMENT AND ANY OFFER IF MADE
SUBSEQUENTLY IS DIRECTED ONLY AT PERSONS WHO ARE "QUALIFIED INVESTORS"
WITHIN THE MEANING OF THE PROSPECTUS REGULATION (REGULATION (EU) 2017/1129)
("QUALIFIED INVESTORS"). IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS DIRECTED
EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN
MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE
FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS
AMENDED (THE "ORDER") OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE
ORDER, AND (III) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED, AND ANY
INVESTMENT ACTIVITY TO WHICH IT RELATES WILL ONLY BE ENGAGED IN WITH SUCH
PERSONS AND IT SHOULD NOT BE RELIED ON BY ANYONE OTHER THAN SUCH PERSONS.

THIS ANNOUNCEMENT MAY INCLUDE STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE,
"FORWARD-LOOKING STATEMENTS". THESE FORWARD-LOOKING STATEMENTS MAY BE
IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE TERMS
"BELIEVES", "ESTIMATES", "PLANS", "PROJECTS", "ANTICIPATES", "EXPECTS",
"INTENDS", "MAY", "WILL" OR "SHOULD" OR, IN EACH CASE, THEIR NEGATIVE OR
OTHER VARIATIONS OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY,
PLANS, OBJECTIVES, GOALS, FUTURE EVENTS OR INTENTIONS. FORWARD-LOOKING
STATEMENTS MAY AND OFTEN DO DIFFER MATERIALLY FROM ACTUAL RESULTS. ANY
FORWARD-LOOKING STATEMENTS REFLECT THE ISSUER'S OR THE COMPANY'S CURRENT
VIEW WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS RELATING TO
FUTURE EVENTS AND OTHER RISKS, UNCERTAINTIES AND ASSUMPTIONS RELATING TO THE
GROUP'S BUSINESS, RESULTS OF OPERATIONS, FINANCIAL POSITION, LIQUIDITY,
PROSPECTS, GROWTH OR STRATEGIES. FORWARD-LOOKING STATEMENTS SPEAK ONLY AS OF
THE DATE THEY ARE MADE. EACH OF THE ISSUER, THE COMPANY, THE JOINT
BOOKRUNNERS AND THEIR RESPECTIVE AFFILIATES EXPRESSLY DISCLAIMS ANY
OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE ANY FORWARD LOOKING
STATEMENT CONTAINED IN THIS ANNOUNCEMENT WHETHER AS A RESULT OF NEW
INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.

THIS PUBLICATION CONSTITUTES NEITHER A PROSPECTUS OR A SIMILAR NOTICE WITHIN
THE MEANING OF THE ARTICLES 35 ET SEQQ. AND 69 OF THE SWISS FINANCIAL
SERVICES ACT OR A LISTING PROSPECTUS WITHIN THE MEANING OF THE APPLICABLE
LISTING RULES OF ANY STOCK EXCHANGE. ANY PURCHASE OF BONDS OF THE ISSUER IN
THE PROPOSED OFFERING SHOULD BE MADE SOLELY ON THE BASIS OF THE INFORMATION
CONTAINED IN THE FINAL PROSPECTUS TO BE ISSUED BY THE ISSUER IN CONNECTION
WITH THE OFFERING. ANY PURCHASE OF SHARES OF THE COMPANY IN THE PROPOSED
OFFERING SHOULD BE MADE SOLELY ON THE BASIS OF PUBLICLY AVAILABLE
INFORMATION. THE INFORMATION IN THIS ANNOUNCEMENT IS SUBJECT TO CHANGE THE
JOINT BOOKRUNNERS ARE ACTING EXCLUSIVELY FOR ISSUER AND THE COMPANY AND
NO-ONE ELSE IN CONNECTION WITH THE OFFERING. THEY WILL NOT REGARD ANY OTHER
PERSON AS THEIR RESPECTIVE CLIENTS IN RELATION TO THE OFFERING AND WILL NOT
BE RESPONSIBLE TO ANYONE OTHER THAN ISSUER AND THE COMPANY FOR PROVIDING THE
PROTECTIONS AFFORDED TO THEIR RESPECTIVE CLIENTS, NOR FOR PROVIDING ADVICE
IN RELATION TO THE OFFERING, THE CONTENTS OF THIS ANNOUNCEMENT OR ANY
TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO HEREIN.

IN CONNECTION WITH THE OFFERING OF THE BONDS AND THE SHARES, THE JOINT
BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY TAKE UP A PORTION OF THE
SECURITIES IN THE OFFERINGS AS A PRINCIPAL POSITION AND IN THAT CAPACITY,
MAY RETAIN, PURCHASE, SELL, OFFER TO SELL FOR THEIR OWN ACCOUNTS SUCH
SECURITIES AND OTHER SECURITIES OF THE ISSUER OR THE COMPANY OR RELATED
INVESTMENTS IN CONNECTION WITH THE OFFERINGS OR OTHERWISE. ACCORDINGLY,
REFERENCES IN THE PROSPECTUS RELATED TO THE BONDS, ONCE PUBLISHED, BEING
ISSUED, OFFERED, SUBSCRIBED, ACQUIRED, PLACED OR OTHERWISE DEALT IN SHOULD
BE READ AS INCLUDING ANY ISSUE OR OFFER TO, OR SUBSCRIPTION, ACQUISITION,
PLACING OR DEALING BY THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES
ACTING IN SUCH CAPACITY. IN ADDITION, THE JOINT BOOKRUNNERS, AND ANY OF
THEIR AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS (INCLUDING SWAPS,
WARRANTS OR CONTRACTS FOR DIFFERENCES) WITH INVESTORS IN CONNECTION WITH
WHICH THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY FROM TIME TO
TIME ACQUIRE, HOLD OR DISPOSE OF SECURITIES OF THE ISSUER OR THE COMPANY.
THE JOINT BOOKRUNNERS DO NOT INTEND TO DISCLOSE THE EXTENT OF ANY SUCH
INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR
REGULATORY OBLIGATIONS TO DO SO.

NONE OF THE JOINT BOOKRUNNERS OR ANY OF THEIR RESPECTIVE DIRECTORS,
OFFICERS, EMPLOYEES, ADVISERS OR AGENTS ACCEPTS ANY RESPONSIBILITY OR
LIABILITY WHATSOEVER FOR OR MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR
IMPLIED, AS TO THE TRUTH, ACCURACY OR COMPLETENESS OF THE INFORMATION IN
THIS ANNOUNCEMENT (OR WHETHER ANY INFORMATION HAS BEEN OMITTED FROM THE
ANNOUNCEMENT) OR ANY OTHER INFORMATION RELATING TO THE ISSUER OR THE
COMPANY, THEIR SUBSIDIARIES OR ASSOCIATED COMPANIES, WHETHER WRITTEN, ORAL
OR IN A VISUAL OR ELECTRONIC FORM, AND HOWSOEVER TRANSMITTED OR MADE
AVAILABLE OR FOR ANY LOSS HOWSOEVER ARISING FROM ANY USE OF THIS
ANNOUNCEMENT OR ITS CONTENTS OR OTHERWISE ARISING IN CONNECTION THEREWITH.

NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS
OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER
IN ANY JURISDICTION. ANY OFFER TO ACQUIRE SECURITIES PURSUANT TO THE
PROPOSED OFFERING WILL BE MADE. ANY INVESTOR SHOULD MAKE HIS INVESTMENT
DECISION FOR THE PURCHASE OF THE SHARES ON PUBLICLY AVAILABLE INFORMATION
AND FOR THE PURCHASE OF THE BONDS SOLELY ON THE BASIS OF THE INFORMATION
THAT IS CONTAINED IN THE PROSPECTUS (THE "PROSPECTUS") PUBLISHED BY THE
COMPANY AND THE ISSUER IN CONNECTION WITH THE OFFERING AND ADMISSION TO
TRADING AND LISTING OF THE BONDS TO BE ISSUED BY THE ISSUER AS DESCRIBED IN
THE PROSPECTUS ON THE SIX SWISS EXCHANGE. COPIES OF THE PROSPECTUS ARE
AVAILABLE FREE OF CHARGE AT [ZUR ROSE GROUP AG, LISA LÜTHI, CORPORATE
COMMUNICATIONS, WALZMÜHLESTRASSE 60, 8500 FRAUENFELD, SWITZERLAND (TELEPHONE
NUMBER: +41 (0)52 724 08 14; EMAIL: LISA.LUETHI@ZURROSE.COM), AND AT UBS AG,
PROSPECTUS LIBRARY, P.O. BOX, CH-8098 ZURICH (TELEPHONE NUMBER: +41 (0)44
239 47 03, FACSIMILE: +41 (0)44 239 69 14 OR EMAIL:
SWISS-PROSPECTUS@UBS.COM), DURING REGULAR BUSINESS HOURS].

---------------------------------------------------------------------------

Ende der Medienmitteilungen

---------------------------------------------------------------------------

   Sprache:        Deutsch
   Unternehmen:    Zur Rose Group AG
                   Walzmühlestrasse 60
                   8500 Frauenfeld
                   Schweiz
   Telefon:        +41 52 724 08 14
   Internet:       www.zurrosegroup.com
   ISIN:           CH0042615283
   Börsen:         SIX Swiss Exchange
   EQS News ID:    1440897

   Ende der Mitteilung    EQS News-Service
---------------------------------------------------------------------------

1440897 13.09.2022 CET/CEST
 ISIN  CH0042615283

AXC0079 2022-09-13/09:26

Relevante Links: Zur Rose Group AG

Copyright dpa-AFX Wirtschaftsnachrichten GmbH. Alle Rechte vorbehalten. Weiterverbreitung, Wiederveröffentlichung oder dauerhafte Speicherung ohne ausdrückliche vorherige Zustimmung von dpa-AFX ist nicht gestattet.